BRIEF-Theratechnologies says 82.5 pct of patients achieved the primary endpoint in late-stage trial of HIV drug

Tue May 24, 2016 7:28am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

May 24 (Reuters) - Theratechnologies

* Notified by partner of results for primary end point of phase iii trial with ibalizumab in patients with multi-drug resistant hiv-1

* Theratechnologies announces that 82.5% of patients achieved the primary endpoint in the phase iii ibalizumab trial Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)